Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F sub(1) mice

• Published in: The Journal of experimental medicine Vol. 179; no. 1; pp. 305 - 310
• Main Authors: Ishida, H, Muchamuel, T, Sakaguchi, S, Andrade, S, Menon, S, Howard, M
• Format: Journal Article
• Language: English
• Published: 01-01-1994
• ISSN: 0022-1007

We have previously shown that continuous administration of anti-interleukin 10 (anti-IL-10) antibodies (Abs) to BALB/c mice modifies endogenous levels of autoantibodies, tumor necrosis factor alpha (TNF- alpha ), and interferon gamma , three immune mediators known to affect the development of autoimmunity in "lupus-prone" New Zealand black/white (NZB/W)F sub(1) mice. To explore the consequences of IL-10 neutralization in NZB/W F sub(1) mice, animals were injected two to three times per week from birth until 8-10 mo of age with anti-IL-10 Abs or with isotype control Abs. The data suggest that IL-10 antagonists may be beneficial in the treatment of human systemic lupus erythematosus.